or search for allinseo plug in" Body Health Advisor » Blog Archive » Advice on Health and Body Matters

Latest alert by FDA for Diabetic Patients

The U.S. FDA has issued an alert on 19 Marc 09 o remind the public that Insulin Pens and Insulin Cartridges Must Not Be Shared.

Originally, this alert was sent to health care professionals reminding them that single-patient insulin pens and insulin cartridges should not be used to administer medication to multiple patients due to the potential risk of transmitting blood-borne pathogens such as HIV and the hepatitis viruses. However, I felt that this is something all diabetic patients should be aware of, so that if it happend to them, they are also well aware of the risks.

What’s the rationale for this alert?
Well, insulin pens are pen-shaped injector devices that contain a disposable needle and either an insulin reservoir or an insulin cartridge. The devices typically contain enough insulin for a patient to self-administer several doses of insulin before the reservoir or cartridge is empty. All insulin pens are approved only for single-patient use (one device for only one patient).

Apparently, the FDA was aware of incidents at two undisclosed hospitals involving more than 2,000 people in which the cartridge component of the insulin pens were used to administer insulin to multiple patients, although the disposable needles were reportedly changed among patients.

“Insulin pens are designed to be safe for one patient to use one pen multiple times with a new, fresh needle for each injection,” said Amy Egan, M.D., deputy director of safety at the FDA’s Division of Metabolism and Endocrinology Products in the Center for Drug Evaluation and Research. “Insulin pens are not designed, and are not safe, for one pen to be used by more than one patient, even if needles are changed between patients due to the risk of transmitting blood-borne pathogens.”

Patients exposed to shared insulin pens are being contacted by the two hospitals and are being offered testing for hepatitis and HIV. Some of the potentially exposed patients have reportedly tested positive for the hepatitis C virus, although it is not known if the virus was spread as a result of insulin pen sharing.

The FDA is working with the Centers for Disease Control and Prevention and professional organizations to address infection control issues related to insulin pens.

For us, as Diabetes patients, please be aware of the risks of sharing insulin catridges. If you see it being done at health care centres, stop the staff immediately and report the incident to the FDA. Also, don’t share the catridges amongst family members. Better safe than sorry!

Technorati Tags:

Tags: , , , , , , , , , , , , , , , , , , , , , , , , ,

3 Responses to “Latest alert by FDA for Diabetic Patients”

  1. Anonymous Says:

    Mom Blogs - Blogs for Moms…

  2. Medifast Says:

    You wouldn’t believe it but I have lost all day searching for some information about this. You’re a lifesaver, it was a interesting read and really helped me out. Cheers,medifast recipes

  3. inexpensive patio furniture Says:

    Hi. I treasured to drop you a quick note to verbalize my thanks. I’ve been observing your blog for a month or so and have plucked up a heap of fabulous information as well as enjoyed the way you’ve structured your site. I am seeking to run my own blog however I think its too general and I would like to focus more on smaller topics.

Leave a Reply

  • Kombiglyze XR as a treatment for type 2 diabetes in adults approved
    Bristol-Myers, AstraZeneca Receive FDA Approval For Diabetes Drug. The AP (11/5) reported, “Drug makers Bristol-Myers Squibb Co. and AstraZeneca PLC said Friday that they received US marketing approval for a once-a-day diabetes drug that combines the starter diabetes drug metformin with the companies’ newer drug Onglyza.” The Food and Drug […]
  • Type 2 Diabetes is increasing in China
    Global research and advisory firm Decision Resources has predicted that the Chinese type 2 diabetes market will grow from $1.4 billion in 2009 to $2.5 billion in 2014. According to the Emerging Markets report entitled Type 2 Diabetes in China, this growth is attributed to an increasing drug-treated population, expanding medical insurance coverage and the [.. […]
  • Avastatin for Breast cancer
    Roche Stands To Lose Substantial Sales Should Regulatory Bodies Revoke License For Avastin. Dow Jones Newswire(12/8, Mijuk) reported that should FDA and European regulators revoke the license for Avastin (bevacizumab) as a treatment for breast cancer, then the drug’s maker, Roche Holding AG, may stand to lose more than one billion Swiss francs in sales […]
  • FDA: Tainted products marketed as dietary supplements potentially dangerous
    Agency working with trade associations to increase company vigilance and protect public In a letter sent today to dietary supplement manufacturers, the U.S. Food and Drug Administration expressed concern about undeclared or deceptively labeled ingredients in products marketed as dietary supplements. These substances include the active ingredients in FDA-a […]
H1N1 Fraudulent Products update







Tai Chi WeightLoss